Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent

[1]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[2]  S. Achenbach,et al.  Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  J. Mehilli,et al.  Collapse of a Bioresorbable Novolimus-Eluting Coronary Scaffold. , 2016, JACC. Cardiovascular interventions.

[4]  L. Kołakowski,et al.  The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. , 2015, Kardiologia polska.

[5]  F. Eberli,et al.  Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. , 2015, Journal of the American College of Cardiology.

[6]  T. Ibrahim,et al.  A potential life-threatening complication after implantation of a bioresorbable scaffold for coronary stenting within a mechanically stressed region , 2015, Clinical Research in Cardiology.

[7]  T. Lüscher,et al.  Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios , 2014, Clinical Research in Cardiology.